{"id":634534,"date":"2023-01-18T16:34:02","date_gmt":"2023-01-18T16:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634534"},"modified":"2023-01-18T16:34:02","modified_gmt":"2023-01-18T16:34:02","slug":"degenerative-disc-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/degenerative-disc-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634534.html","title":{"rendered":"Degenerative Disc Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1674034894.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Degenerative Disc Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1674034894.jpeg\" alt=\"Degenerative Disc Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Degenerative Disc Disease Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s &#8216;Degenerative Disc Disease Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Degenerative Disc Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Degenerative Disc Disease pipeline domain.<\/div>\n<p style=\"text-align: justify;\">United States, Nevada, Las Vegas, DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Degenerative Disc Disease Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Degenerative Disc Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Degenerative Disc Disease pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Degenerative Disc Disease Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 30+ Degenerative Disc Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Degenerative Disc Disease market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Degenerative Disc Disease companies developing novel drug candidates to improve the Degenerative Disc Disease treatment landscape include<strong> Affibody, Celgene Corporation, UCB, <\/strong>and others.<\/li>\n<li>Promising Degenerative Disc Disease pipeline therapies in various stages of development include<strong> Izokibep<\/strong>, <strong>CC 99677, Bimekizumab, <\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Degenerative Disc Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Degenerative disc disease (spondylosis) is used to describe the regular changes that occur in human spinal discs as they age. The discs usually act as shock absorbers for the human spine, which allows the body to flex, bend, and twist. With aging, there are several other factors, such as the drying out of the disc, tears in the outer core of the disc during daily activities, and sports and injuries leading to swelling, soreness, and instability, contributing to the development of degenerative disc disease. This disease often leads to multiple types of disorders, such as lumbar spinal stenosis, spondylolisthesis, and retrospondylolisthesis.&nbsp;<\/p>\n<p style=\"text-align: justify;\">About 90% of people experience an episode of debilitating back pain at a later point in their lives. The majority of cases experienced are asymptomatic. The spinal disks are made up of a soft inner core and a tough outer wall. The disks change in ways that may cause degenerative disk disease, such as: Dry out (When a person is born, the disks in the spine are mostly made up of water. As a person ages, they lose water and get thinner. Flatter disks can&#8217;t absorb shocks as well.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The water loss also means less cushion or padding between the vertebrae. This can lead to other problems in the spine that may cause pain and Crack (the stress of everyday movements and minor injuries over the years can cause tiny tears in the outer wall, which contains nerves. Any tears near the nerves can become painful. And if the wall breaks down, the disk&#8217;s soft core may push through the cracks. The disk may bulge, or slip out of place, which is called a slipped or herniated disk. It can affect nearby nerves. In some cases, degenerative disk disease can lead to numbness and tingling in the arms and legs. It can also cause the leg muscles to become weak. This means the damaged disks may be affecting the nerves near the spine. The goal is to ease pain and stop more damage.&nbsp;<\/p>\n<p style=\"text-align: justify;\">If other treatments don&#8217;t work, doctor may recommend surgery. One procedure, called a discectomy, removes the injured part of the disk. This helps take pressure off the nerves. In some cases, the doctor might remove the whole disk and put an artificial one in. If person have a severe problem, the doctor might fuse (permanently connect) the bones in the spine after they remove the disk.<\/p>\n<p style=\"text-align: justify;\"><strong>Degenerative Disc Disease Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CC 99677: Celgene Corporation<\/strong><\/p>\n<p style=\"text-align: justify;\">Celgene Corporation, is developing a drug CC 99677, as a treatment for ankylosing spondylitis (AS). The CC-99677 inhibition of MK2 is a promising approach for the treatment of inflammatory diseases. Currently, Phase II study of CC-99677 in patients with, ankylosing spondylitis (AS) is undergoing.<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Degenerative Disc Disease drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Degenerative Disc Disease Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Degenerative Disc Disease Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Affibody<\/li>\n<li>Celgene Corporation<\/li>\n<li>UCB<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Degenerative Disc Disease Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Izokibep<\/li>\n<li>CC 99677<\/li>\n<li>Bimekizumab<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Degenerative Disc Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Degenerative Disc Disease Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Degenerative Disc Disease Companies<\/strong>: Affibody, Celgene Corporation, UCB, and others<\/li>\n<li><strong>Key Degenerative Disc Disease Pipeline Therapies<\/strong>: Izokibep, CC 99677, Bimekizumab, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Degenerative Disc Disease treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Degenerative Disc Disease Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about the leading companies in the<\/strong>&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/degenerative-disc-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Degenerative Disc Disease&nbsp;pipeline domain<\/a>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=degenerative-disc-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=degenerative-disc-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Degenerative Disc Disease Pipeline Insights DelveInsight\u2019s &#8216;Degenerative Disc Disease Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Degenerative Disc Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/degenerative-disc-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634534.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-634534","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634534"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}